None listed
Conditions
Brief summary
This study aims to improve the scientific understanding of the effects of intramuscularly (IM) administered 5-MeO-DMT on human brain activity as well as other indexes of well-being as assessed through psychological, physiological, and biological markers. Finally, we aim to further our understanding of the tolerability and safety profile as well as dose-dependent effects of different doses of 5-MeO-DMT or placebo administered per intramuscular administration and to uncover its phenomenological characteristics.
Interventions
The study employs a single-blind design (only the researchers will know the dosing regimen) involving 15 healthy volunteers. Following successful screening, and after consent is obtained, there will be 4 dosing days, each spaced 2 weeks apart. The four dosing days will involve IM administration of 5-MeO-DMT (3 mg, 6 mg and 9 mg) and inactive placebo. A psychiatrist/medical practitioner will administer the intervention.
Sponsors
Swinburne University of Technology, Hawthorn
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Physically and mentally healthy. Good command of the English language. Prior experience with a psychedelic without experiencing adverse events. Normal baseline ECG (determined by study medic). Informed consent. No psychedelic use within 2 weeks prior to the experiment. Email access. No anaemia. Normal healthy body mass index (i.e., between 18.5-24.9). Not use caffeine or nicotine 2 hours before or 6 hours after the dose.
Exclusion criteria
Not physically and mentally healthy. No command of the English language. No prior experience with a psychedelic without experiencing adverse events. Abnormal baseline ECG (determined by study medic). No informed consent. Psychedelic use within 2 weeks prior to the experiment. No email access. Anaemia. Abnormal body mass index (i.e., below 18,5 or above 24,9). Not use caffeine or nicotine 2 hours before or 6 hours after the dose.
Outcome results
None listed